Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Clear Cell Tumor

Stomach Neoplasms

Clear-cell metastatic renal cell carcinoma

Head and Neck Neoplasms

Triple Negative Breast Neoplasms

Melanoma, Neoplasms

Oligometastatic Renal Cell Carcinoma

Hodgkin Disease

Colorectal Cancer Metastatic

Hodgkin Disease

Hodgkin Disease

Neoplasm Metastasis, Triple Negative Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Carcinoma, Renal Cell, Kidney Neoplasms

Ovarian Neoplasms

Lung Neoplasms

Mesothelioma, Malignant

Vulvar Neoplasms, Neoplasms, Squamous Cell

Urologic Neoplasms

Colorectal Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NSCLC With COPD

Head and Neck Neoplasms

Carcinoma, Renal Cell, Melanoma

Carcinoma, Non-Small-Cell Lung

Uterine Cervical Neoplasms

PD-1 Antibody

Neoplasm Metastasis, Prostatic Neoplasms

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Stomach Neoplasms

Neoplasm Metastasis, Pancreatic Neoplasms

Squamous Cell Carcinoma of Head and Neck

Triple Negative Breast Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma

MSI-H Advanced Colorectal Cancer

Locally Advanced Cervical Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Transitional Cell

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Carcinoma, Renal Cell

Clinical Trials

KeyPemls-004

PEACOCC

Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive

Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer

Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

Neo Trio

PE-PE

PLIMATH

POCHI

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)

KEYPAD

Keynote-695

MITO28MaNGOov4

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

MiST

Apollo

Pembro-SRT

PEMBROLA

PROMPT

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD

Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer

REFINE

Luscid

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)

Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

EPIC-1

FOCUS

c-TRAK-TN

MITO 27

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

MITO CERV 3

DYNAPET

RESPONDER

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

PANDORA